{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:51:09Z","timestamp":1794282669237,"version":"4.9.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Waikato Hospital Neurology Research Fund","award":["Waikato Hospital Neurology Research Fund"],"award-info":[{"award-number":["Waikato Hospital Neurology Research Fund"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metabolic dysfunction is an important factor in the pathogenesis of motor neuron disease, but its prevalence and association with survival in this disorder is unknown. We hypothesized that patients with motor neuron disease would show a higher prevalence of metabolic syndrome compared to the general New Zealand population, and that metabolic syndrome would be associated with worsened survival. We undertook a retrospective analysis in 109 motor neuron disease patients diagnosed and treated at Waikato Hospital from 2013 to 2020. Demographic, clinical, and laboratory data were collected. Survival was defined as the date of initial symptom onset to the date of death. Of 104 eligible patients, 34 patients (33%) had metabolic syndrome (33% of Europeans, 46% of M\u0101ori). Mean survival in motor neuron disease patients with metabolic syndrome was significantly reduced compared to patients without metabolic syndrome (38 vs. 61 months, <jats:italic>P<\/jats:italic>\u2009=\u20090.044), with a 5-year survival rate of 21% for the former and 38% for the latter (<jats:italic>P<\/jats:italic>\u2009=\u20090.012). Compared with the general New Zealand population, metabolic syndrome is highly prevalent amongst motor neuron disease patients in the Waikato region and it is associated with worsened survival. Metabolic dysfunction may be a key factor underlying the pathogenesis of motor neuron disease.<\/jats:p>","DOI":"10.1007\/s11011-023-01296-2","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:02:26Z","timestamp":1695621746000},"page":"2583-2589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of the metabolic syndrome on prevalence and survival in motor neuron disease: a retrospective case series"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7055-7101","authenticated-orcid":false,"given":"Jee Eun","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1685-8920","authenticated-orcid":false,"given":"Jee Ah","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Demopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-7766","authenticated-orcid":false,"given":"Matthew CL","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"1296_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","volume":"23","author":"KGMM Alberti","year":"2006","unstructured":"Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23:469\u2013480","journal-title":"Diabet Med"},{"key":"1296_CR2","unstructured":"Australian Bureau of Statistics [Internet]. Belconnen (AU): Australian Bureau of Statistics [cited 2023 Jun 13]. Available from: https:\/\/www.abs.gov.au\/"},{"key":"1296_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/14737175.2020.1788389","volume":"20","author":"H Blasco","year":"2020","unstructured":"Blasco H, Lanznaster D, Veyrat-Durebex C et al (2020) Understanding and managing metabolic dysfunction in amyotrophic lateral sclerosis. Expert Rev Neurother 20:907\u2013919","journal-title":"Expert Rev Neurother"},{"key":"1296_CR4","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3389\/fneur.2019.01205","volume":"10","author":"MD Brito","year":"2019","unstructured":"Brito MD, da Silva GFG, Tilieri EM et al (2019) Metabolic alteration and amyotrophic lateral sclerosis outcome: a systematic review. Front Neurol 10:1205","journal-title":"Front Neurol"},{"key":"1296_CR5","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1212\/WNL.0b013e3181c1df1e","volume":"73","author":"A Chi\u00f2","year":"2009","unstructured":"Chi\u00f2 A, Calvo A, Ilardi A et al (2009) Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 73:1681\u20131685","journal-title":"Neurology"},{"key":"1296_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1212\/01.wnl.0000285080.70324.27","volume":"70","author":"L Dupuis","year":"2008","unstructured":"Dupuis L, Corcia P, Fergani A et al (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70:1004\u20131009","journal-title":"Neurology"},{"key":"1296_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1474-4422(10)70224-6","volume":"10","author":"L Dupuis","year":"2011","unstructured":"Dupuis L, Pradat P-F, Ludolph AC et al (2011) Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 10:75\u201382","journal-title":"Lancet Neurol"},{"key":"1296_CR8","unstructured":"EHINZ [Internet]. Wellington (NZ): Environmental Health Intelligence New Zealand [cited 2023 Jun 13]. Available from: https:\/\/ehinz.ac.nz\/indicators\/population-vulnerability\/socioeconomic-deprivation-profile\/"},{"key":"1296_CR9","first-page":"U2399","volume":"120","author":"D Gentles","year":"2007","unstructured":"Gentles D, Metcalf P, Dyall L et al (2007) Metabolic syndrome prevalence in a multicultural population in Auckland, New Zealand. NZ Med J 120:U2399","journal-title":"NZ Med J"},{"key":"1296_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1600-0404.1964.tb04265.x","volume":"40","author":"V Ion\u01ce\u015fescu","year":"1964","unstructured":"Ion\u01ce\u015fescu V, Luca N (1964) Studies on carbohydrate metabolism in amyotrophic lateral sclerosis and hereditary proximal spinal muscular atrophy. Acta Neurol Scand 40:47\u201357","journal-title":"Acta Neurol Scand"},{"key":"1296_CR11","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","volume":"377","author":"MC Kiernan","year":"2011","unstructured":"Kiernan MC, Vucic S, Cheah BC et al (2011) Amyotrophic lateral sclerosis. Lancet 377:942\u2013955","journal-title":"Lancet"},{"key":"1296_CR12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/jamaneurol.2015.0910","volume":"72","author":"M-A Kioumourtzoglou","year":"2015","unstructured":"Kioumourtzoglou M-A, Rotem RS, Seals RM et al (2015) Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol 72:905\u2013911","journal-title":"JAMA Neurol"},{"key":"1296_CR13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/cells9041065","volume":"9","author":"M Kodavati","year":"2020","unstructured":"Kodavati M, Wang H, Hegde ML (2020) Altered mitochondrial dynamics in motor neuron disease: an emerging perspective. Cells 9:1065","journal-title":"Cells"},{"key":"1296_CR14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/WCO.0000000000000730","volume":"32","author":"E Longinetti","year":"2019","unstructured":"Longinetti E, Fang F (2019) Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol 32:771\u2013776","journal-title":"Curr Opin Neurol"},{"key":"1296_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mito.2005.01.002","volume":"5","author":"G Manfredi","year":"2005","unstructured":"Manfredi G, Xu Z (2005) Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion 5:77\u201387","journal-title":"Mitochondrion"},{"key":"1296_CR16","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/ene.14393","volume":"27","author":"P Masrori","year":"2020","unstructured":"Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 27:1918\u20131929","journal-title":"Eur J Neurol"},{"key":"1296_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000369812","volume":"15","author":"CS Mitchell","year":"2015","unstructured":"Mitchell CS, Hollinger SK, Goswami SD et al (2015) Antecedent disease is less prevalent in amyotrophic lateral sclerosis. Neurodegener Dis 15:109\u2013113","journal-title":"Neurodegener Dis"},{"key":"1296_CR18","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1080\/21678421.2017.1336560","volume":"18","author":"C Moglia","year":"2017","unstructured":"Moglia C, Calvo A, Canosa A et al (2017) Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotroph Lateral Scler Frontotemporal Degener 18:590\u2013597","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1296_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/archneur.1979.00500400071011","volume":"36","author":"Y Nagano","year":"1979","unstructured":"Nagano Y, Tsubaki T, Chase TN (1979) Endocrinologic regulation of carbohydrate metabolism. Amyotrophic lateral sclerosis and parkinsonism-dementia on Guam. Arch Neurol 36:217\u2013220","journal-title":"Arch Neurol"},{"key":"1296_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3109\/21678421.2012.735240","volume":"14","author":"\u00c9J O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly \u00c9J, Wang H, Weisskopf MG et al (2013) Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 14:205\u2013211","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1296_CR21","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.3390\/ijms22126352","volume":"22","author":"E Obrador","year":"2021","unstructured":"Obrador E, Salvador-Palmer R, L\u00f3pez-Blanch R et al (2021) The link between oxidative stress, redox status, bioenergetics and mitochondria in the pathophysiology of ALS. Int J Mol Sci 22:6352","journal-title":"Int J Mol Sci"},{"key":"1296_CR22","doi-asserted-by":"publisher","first-page":"165838","DOI":"10.1016\/j.bbadis.2020.165838","volume":"1866","author":"P Prasun","year":"2020","unstructured":"Prasun P (2020) Mitochondrial dysfunction in metabolic syndrome. Biochim Biophys Acta Mol Basis Dis 1866:165838","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1296_CR23","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3109\/21678421.2015.1062517","volume":"16","author":"MK Rafiq","year":"2015","unstructured":"Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ (2015) Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: insights from the olesoxime clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 16:478\u2013484","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1296_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/0022-510X(84)90154-0","volume":"63","author":"ET Reyes","year":"1984","unstructured":"Reyes ET, Perurena OH, Festoff BW et al (1984) Insulin resistance in amyotrophic lateral sclerosis. J Neurol Sci 63:317\u2013324","journal-title":"J Neurol Sci"},{"key":"1296_CR26","doi-asserted-by":"publisher","first-page":"18916","DOI":"10.1038\/s41598-021-97928-7","volume":"11","author":"T Singh","year":"2021","unstructured":"Singh T, Jiao Y, Ferrando LM et al (2021) Neuronal mitochondrial dysfunction in sporadic amyotrophic lateral sclerosis is developmentally regulated. Sci Rep 11:18916","journal-title":"Sci Rep"},{"key":"1296_CR27","doi-asserted-by":"publisher","first-page":"132933","DOI":"10.1016\/j.neulet.2017.06.052","volume":"710","author":"EF Smith","year":"2019","unstructured":"Smith EF, Shaw PJ, De Vos KJ (2019) The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett 710:132933","journal-title":"Neurosci Lett"},{"key":"1296_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2188\/jea.JE20140176","volume":"25","author":"Y Sun","year":"2015","unstructured":"Sun Y, Lu C-J, Chen R-C (2015) Risk of amyotrophic lateral sclerosis in patients with diabetes: a nationwide population-based cohort study. J Epidemiol 25:445\u2013451","journal-title":"J Epidemiol"},{"key":"1296_CR29","first-page":"611","volume":"10","author":"TW Tefera","year":"2016","unstructured":"Tefera TW, Borges K (2016) Metabolic dysfunctions in amyotrophic lateral sclerosis pathogenesis and potential metabolic treatments. Front Neurosci 10:611","journal-title":"Front Neurosci"},{"key":"1296_CR30","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s00415-019-09405-x","volume":"266","author":"C-P Tsai","year":"2019","unstructured":"Tsai C-P, Lee JK-W, Lee CT-C (2019) Type II diabetes mellitus and the incidence of amyotrophic lateral sclerosis. J Neurol 266:2233\u20132243","journal-title":"J Neurol"},{"key":"1296_CR31","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1007\/s12035-015-9165-7","volume":"53","author":"GN Valbuena","year":"2016","unstructured":"Valbuena GN, Rizzardini M, Cimini S et al (2016) Metabolomic analysis reveals increased aerobic glycolysis and amino acid deficit in a cellular model of amyotrophic lateral sclerosis. Mol Neurobiol 53:2222\u20132240","journal-title":"Mol Neurobiol"},{"key":"1296_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.phrs.2018.09.008","volume":"138","author":"Y Xiao","year":"2018","unstructured":"Xiao Y, Karam C, Yi J et al (2018) ROS-related mitochondrial dysfunction in skeletal muscle of an ALS mouse model during the disease progression. Pharmacol Res 138:25\u201336","journal-title":"Pharmacol Res"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-023-01296-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-023-01296-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-023-01296-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:17:06Z","timestamp":1700554626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-023-01296-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1296"],"URL":"https:\/\/doi.org\/10.1007\/s11011-023-01296-2","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"assertion":[{"value":"12 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in this study were prospectively approved by the Central Health and Disability Ethics Committee of NZ.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}